Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.

ABSTRACT:

Importance

Risankizumab selectively inhibits interleukin 23, a cytokine that contributes to psoriatic inflammation.

Objective

To evaluate the efficacy and safety of risankizumab vs placebo and continuous treatment vs withdrawal in adults with moderate to severe plaque psoriasis.

Design, setting, and participants

Multinational, phase 3, randomized, double-blind, placebo-controlled trial conducted from March 6, 2016, to July 26, 2018. A total of 507 eligible patients had stable moderate to severe chronic plaque psoriasis for 6 months or longer, body surface area involvement greater than or equal to 10%, Psoriasis Area and Severity Index (PASI) greater than or equal to 12, and a static Physician's Global Assessment (sPGA) score greater than or equal to 3. Intention-to-tr

SUBMITTER: Blauvelt A 

PROVIDER: S-EPMC7142813 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature